methyl 2-(4-fluoro-3-methylphenyl)-4-oxo-6,6-dimethyl-cyclohex-2-enecarboxylate | 129083-90-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(4-fluoro-3-methylphenyl)-4-oxo-6,6-dimethyl-cyclohex-2-enecarboxylate
• 英文别名: methyl 2-(4-fluoro-3-methylphenyl)-4-oxo-6,6-dimethylcyclohex-2-en-1-carboxylate；Methyl 2-(4-fluoro-3-methylphenyl)-6,6-dimethyl-4-oxocyclohex-2-ene-1-carboxylate
• CAS: 129083-90-5
• 化学式: C₁₇H₁₉FO₃
• 分子量: 290.334
• InChiKey: AZSVPZHAKMIGSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-(4-fluoro-3-methylphenyl)-4-oxo-6,6-dimethyl-cyclohex-2-enecarboxylate 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 Methyl 2-(4-fluoro-3-methylphenyl)-4-hydroxy-6, 6-dimethyl-cyclohex-2-en-1-carboxylate
  参考文献：
  名称：

  Inhibitors of HMG-CoA reductase. Biological effects of A 6-[2-[2-(4-fluoro-3-methylphenyl)-4-substituted cyclohexe-1-en-1-yl]ethenyl]-4-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-one

  摘要：

  We report on a series of potent inhibitors of HMG-CoA reductase (HMGR) that were designed to examine the biological consequences that result from molecular changes in RG 12561. The introduction of functional groups on the cyclohexene nucleus of RG 12561 and the resulting inhibitor-enzyme interactions at remote binding sites of HMGR are discussed. Cellular membrane permeability may also contribute to potency. The HMGR inhibitory activity was measured utilizing solubilized enzyme. The compounds were evaluated as inhibitors of sterol biosynthesis in vitro using liver slices and in vivo after oral administration to the rat.

  DOI：

  10.1016/0223-5234(92)90095-i
• 作为产物：
  描述：

  4-氟-3-甲基苯乙酮 在 三氟化硼乙醚 、 苄基三甲基氢氧化铵 、 sodium hydride 作用下， 以 乙醚 为溶剂， 反应 3.0h， 生成 methyl 2-(4-fluoro-3-methylphenyl)-4-oxo-6,6-dimethyl-cyclohex-2-enecarboxylate
  参考文献：
  名称：

  Inhibitors of HMG-CoA reductase. Biological effects of A 6-[2-[2-(4-fluoro-3-methylphenyl)-4-substituted cyclohexe-1-en-1-yl]ethenyl]-4-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-one

  摘要：

  We report on a series of potent inhibitors of HMG-CoA reductase (HMGR) that were designed to examine the biological consequences that result from molecular changes in RG 12561. The introduction of functional groups on the cyclohexene nucleus of RG 12561 and the resulting inhibitor-enzyme interactions at remote binding sites of HMGR are discussed. Cellular membrane permeability may also contribute to potency. The HMGR inhibitory activity was measured utilizing solubilized enzyme. The compounds were evaluated as inhibitors of sterol biosynthesis in vitro using liver slices and in vivo after oral administration to the rat.

  DOI：

  10.1016/0223-5234(92)90095-i

文献信息

• HMG-COA reductase inhibitors
  申请人：Rorer Pharmaceutical Corp.

  公开号：US04900754A1

  公开（公告）日：1990-02-13

  Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof. Pharmaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.

  本发明涉及一种新的3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂，其可以作为抗高胆固醇药物使用，其化学式为##STR1## 以及由此衍生的相应开环羟基酸及其药学上可接受的盐。本发明还涉及含有上述化合物的药物组合物以及使用该药物组合物抑制胆固醇生物合成的方法。
• REGAN, JOHN R.;NEUENSCHWANDER, KENT W.
  作者：REGAN, JOHN R.、NEUENSCHWANDER, KENT W.

  DOI：——

  日期：——
• [EN] NOVEL HMG-CoA REDUCTASE INHIBITORS
  申请人：RORER INTERNATIONAL (OVERSEAS) INC.

  公开号：WO1991013616A1

  公开（公告）日：1991-09-19

  (EN) Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by formula (I), and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof. Pharmaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.(FR) L'invention concerne de nouveaux inhibiteurs de 3-hydroxy-3-méthylglutaryl-coenzyme A réductase utiles en tant qu'agents antihypercholestérolémiques représentés par la formule (I), et les acides hydroxy à anneaux ouverts correspondants dérivés de ces derniers ainsi que leurs sels pharmaceutiquement acceptables. L'invention concerne également des compositions pharmaceutiques renfermant lesdits composés ainsi qu'un procédé permettant d'inhiber la biosynthèse du cholestérol avec ces derniers.